ASH 2024 | Chemo-free regimen of inotuzumab + blinatumomab as frontline therapy in older patients with Ph-B-ALL
Jayastu Senapati
• 7 Dec 2024
Jayastu Senapati, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the feasibility of utilizing a chemotherapy-free regimen of inotuzumab ozogamicin plus blinatumomab in older patients with Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). An ongoing Phase Ib/II trial of this combination in patients over 70 years of age has shown promising results; however, longer-term follow-up data is needed to confirm these. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
